OxTalks is Changing
On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Altering the Vasculature to Promote Tumour Immunity
The journal Science voted “Cancer Immunotherapy” the most important scientific breakthrough in 2013 due in part to the success of adoptive T cell therapy. However, the success of this treatment and others may be limited by the failure of activated lymphocytes to effectively infiltrate tumors. Using an established mouse model where carcinogen-induced tumours arise in vivo, we have reported that depletion of Foxp3+ regulatory T cells (Tregs), can promote development of specialised blood vessels (high endothelial venules or HEV) in tumours. HEV are normally found only in secondary lymphoid tissue where they facilitate transit of naïve and central memory T cells into the lymph node parenchyma. However, in a recent study HEV have been detected in breast tumours where a significant association between HEV presence and density of tumour-infiltrating lymphocytes (TIL) was observed. Significantly a correlation between the presence of HEV and a favourable prognosis in breast cancer and melanoma patients was reported. In our mouse model of tumorigenesis we also found that the presence of intra-tumoural HEV correlated with a significant increase in the number of TIL and control of tumour growth. Thus, the main objectives of our current work are to determine how HEVs are induced in tumours and the role Tregs play in this process and to test novel immunotherapeutic approaches to drive intra-tumoural HEV neogenesis using established pre-clinical mouse models of cancer. The overall aim is to devise new treatments, combining immunotherapy with regimes designed to alter the tumour vasculature.
Date:
1 February 2016, 12:00
Venue:
Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details:
Bernard Sunley Lecture Theatre
Speaker:
Prof Awen Gallimore (University of Cardiff)
Organising department:
Kennedy Institute of Rheumatology
Organiser:
Gintare Kolesnikovaite (Kennedy Institute of Rheumatology)
Organiser contact email address:
Gintare.Kolesnikovaite@kennedy.ox.ac.uk
Host:
Prof Kim Midwood (Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Roosevelt Drive, Oxford OX3 7FY)
Part of:
Kennedy Institute Seminars
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Gintare Kolesnikovaite
